In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA ...
Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall ...
Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators. At two years, ...
WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent ...
Eli Lilly enters three separate acquisitions totaling $3.83 billion in a push into vaccines and infectious diseases, signaling a strategic expansion into prevention-focused medicines. Eli Lilly ...
Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.
Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s ...
VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old. FDA briefing materials emphasize eroding sequencing ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results